Table 2.
Measured pemetrexed concentrations in plasma from NSCLC patients (n = 3)
| Patient code | Pemetrexed concentration (pmol/μL)a mean (SD) | Genderb | Age |
|---|---|---|---|
| A | 80.0 (9.3) | f | 51 |
| A | 142.7 (20.3)c | f | 51 |
| B | 8.7 (1.4) | f | 56 |
| C | 63.0 (7.0) | m | 66 |
| C | 60.7 (8.3)c | m | 66 |
| D | 33.3 (4.9) | m | 75 |
| E | 42.7 (9.7) | m | 48 |
| F | 49.1 (10.8) | f | 56 |
| G | 121.0 (20.2) | m | 61 |
aResults summarize 10 spots per patient sample
bFemale (f) and male (m)
cSecond administration of 500 mg/m2, 3 weeks after first administration